

Volume 1

Subject Index

- Aberrant crypt formation**, 454, 458
- Abl kinases**
cytostatic function, 390
peroxiredoxins, 389
protein structure, 390
- Acetoacetate**, diabetes, 212, 214
- Acetylcholine**
aortic rings, 223
diabetes, 222
relaxation, 223
- Acetylcysteine**
free radicals, 35
lung diseases, 7
- Acquired immunodeficiency syndrome (AIDS)**
dementia, 489
glutathione, 246
thiols, 205
see also Human immunodeficiency virus
- Actin reorganization**
biochemistry, 32
image analysis, 31
membrane ruffling, 29
morphology, 37
Rac proteins, 29–40
signaling pathways, 29
superoxide production, 29–40
- Activator protein 1**
antioxidant regulation, 181–190
binding activity, 320
EMSA studies, 319
ischemia-reperfusion, 317–323
lung inflammation, 428
NO activation, 451
peroxiredoxins, 391, 395
redox regulation, 317–323
- Active oxygen**, ginkgo biloba, 473
- Acute lymphoblastic leukemia (ALL)**, 395
- Acyl chains**
lipid blayers, 344
oxidative damage, 327
- Adeno-associated virus**, gene therapy, 13
- Adenosine diphosphate (ADP)**, 513, 516
- Adenosine dihydrophoribose**
calmodulin interaction, 61–65
sarcolemmic reticulum, 55–67
superoxides, 55–67
synthesis, 59
- Adenosine triphosphate (ATP)**
IRK accessibility, 52
nervous system, 134
NO effects, 510, 516
prostate cancer, 77
- Adenoviral vectors**
gene therapy, 12
Rac expression, 34
- Adhesion molecules**, 83–93
endothelial cells, 83
flow cytometry, 89
lipoxigenase expression, 83
nuclear factors, 83
- Adipocytes**, lipoic acid, 524
- Adrenal glucocorticoids**, stress responses, 403
- Adult respiratory distress syndrome (ARDS)**
gene therapy, 7, 15
hyperoxia, 8, 15
inflammation, 426
lung damage, 15
oxidative stress, 436
redox imbalance, 428
redox regulation, 7
sepsis-induced, 7
- Adult T-cell leukemia (ATL)**, 156
- Advanced glycation end products**, 137
- Aerobic exercise**, free radicals, 537–544
- Aging**
cardiovascular disease, 233
ginkgo biloba, 474
IRK activity, 45
oxidative stress, 72, 474
PBN effects, 481, 487
- Alanine**, NO effect, 47
- Alcohol dehydrogenase**, 259
- Aldehyde dehydrogenase**, 259
- Aldehydes**, cell function, 256
- Alveolitis-fibrosis**, radiation-induced, 14
- Alzheimer's disease**
early-onset, 136
ginkgo biloba, 474
peroxiredoxins, 386
ROI involvement, 134
- Amidothionophosphates (AMTP)**
antioxidants, 325–337
copper chelates, 329, 335
LDL oxidation, 325–337
MRI measurements, 329
peroxide removal, 328
structure, 326
synthesis, 326
- Amyotrophic lateral sclerosis (ALS)**, 135, 474
- Amytal**, mitochondrial inhibitor, 99
- Androgens**, prostate cancer, 71–79
- Angiogenesis**, NO activity, 454
- Angioplasty**, redox-mediated, 6
- Angiotensin**
arachidonic acid, 167–176
homocysteine modulation, 233
oxidase activation, 167
signaling, 233–236
VSMC hypertrophy, 167–176
- Anticancer agents**, cytotoxicity, 563
- Anti-inflammatory drugs**, lung cells, 435
- Antimyxin A**, 77, 99
- Antioxidant protein 2**
activity model, 579
cell signaling, 580
gene and protein, 573
multigene family, 574
pathogenesis, 580
signal transduction, 581
structure and function, 571
thiol-specific, 571–582
- Antioxidants**
activator proteins, 181–190
chronic diseases, 124, 127
cross-talk, 409–416
defense systems, 415
diabetes, 524
dietary supplements, 79
endogenous, 239–244
endothelial dysfunction, 222
free radicals, 34
inorganic, 542
LDL oxidation, 325–337
lipid peroxidation, 547–553
metabolic, 361
neuroprotective agents, 136
nonprotein, 540
nuclear factors, 8
nutrition, 3, 79
peripheral systems, 409–416
phenolic, 433
prostate cancer, 72
public opinion, 3
scavenging activity, 540
stress responses, 409–416
structures, 242
synthetic, 239–244
thiol-specific, 571–582
TNF signaling, 181–190
types, 131, 136
unique compounds, 326
see also specific antioxidant
- Aortic cells**, oxidant production, 34
- Aortic rings**, contraction, 223
- Apoptosis**
acetoacetate, 215
antioxidants, 181
arginine metabolism, 453
B-cells, 305–312
Bcl blocking, 323
carcinogenesis, 452
ginkgo biloba, 474
ischemia-reperfusion, 321

- Apoptosis (*continued*)
 lysosomes, 305–312
 MAPK activation, 502
 mitochondria, 285–294
 NADPN levels, 288
 NO-induced, 452
 oxidative stress, 305–312
 PBN effects, 489
 peroxiredoxins, 391, 395
 proanthocyanidins, 565
 redox changes, 286
 ROS generation, 285–294
 RNS activity, 450
 TNF-induced, 181, 285
- Arachidonic acid
 angiotensin effects, 167
 metabolic pathways, 172
 oxidase activation, 167
 VSMC hypertrophy, 167–176
- Arginine metabolism, tumorigenesis, 453
- Arteriosclerosis
 active oxygen, 474
- Ascorbic acid
 saliva, 542
 scavenging activity, 542
 SRF inhibition, 126
- Asthma, inflammation, 426
- Astrocytes, 139
- Atherogenesis
 foam cells, 585–591
 LDL activity, 586
 lipid hydroperoxides, 93
 monocytes, 211
 oxidants, 585–591
see also Arteriosclerosis
- Atherosclerosis
 cell growth, 167
 diabetes, 216, 523
 ginkgo biloba, 477
 homocysteine, 365, 368
 hydrononenal, 258, 269
 lipoxygenase activity, 83, 93
 oxidative damage, 523, 547
 pathogenesis, 215
 peroxiredoxins, 386
 redox-mediated, 6
 thiols, 205
see also Free radicals
- Autophagy, lysosomes, 306
- Autophosphorylation, insulin-induced, 46, 50
- Azacytidine, macrophages, 297–303
- Azo compounds, ginkgo biloba, 471
- Azomethane, colon carcinogenesis, 455
- B-cells**
 apoptosis, 305–312
 EBV replication, 156
 laser micrography, 309
 lysosomal stability, 305
 necrosis, 305–312
 oxidative stress, 305
- secretory granules, 306
- Bacteria**
 colon carcinogenesis, 456
 HIV expression, 107
 infection, 456
 meningitis, 482
 oxidative stress, 265
 ROS generation, 456
- Baicalein, cytotoxicity, 170
- Bcl proteins, proanthocyanidins, 565
- Beta-carotene, toxicity, 393
- Beta-hydroxybutyrate (BHB), 212
- Bile acids, 450, 456
- Biological antioxidants, 124
- Biomarkers, colon cancer, 457
- Biothiols
 fibroblasts, 123–127
 homocysteine, 123
 lipoic acid, 123
 redox state, 126
 types, 123
- Blood flow, ginkgo biloba, 475
- Blood glucose, lipoic acid, 527
- Body weight, colitis, 559
- Brain tissue
 damage, 485
 ginkgo biloba, 473
 heat shock, 302
 lipid peroxidation, 473
 PBN effects, 485
- Bronchitis, redox imbalance, 428
- Buthionine sulfoximine (BSO), 47, 201
- Butylated hydroxyanisole (BHA), 182
- Butylated hydroxytoluene (BHT), 182
- Cadmium, copper binding, 350, 353**
- Calcium**
 cardiac myofilaments, 509
 chelators, 115, 118
 ERK activation, 501–506
 hydroxynonenal, 261–263
 intracellular, 145, 501
 ischemia, 145–152
 JNK activation, 115, 501
 lung cells, 145–152
 MAPK activation, 501–506
 membrane depolarization, 151
 NO effects, 509–520
 SAPK activation, 113, 501
 signaling, 261–263
- Calmodulin, sarcoplasmic reticulum, 55–67
- Calpromotin, 392
- Cancer**
 biology, 395
 leukemogenesis, 395
 oxidative damage, 72, 547
 peroxiredoxins, 395
 thiols, 205
see also specific cancer
- Carcinogenesis**
 PBN effects, 488
 ROS involvement, 449
see also Colon carcinogenesis
- Cardiac infarction, gene therapy, 6**
- Cardiomyocytes, apoptosis, 322
- Cardiovascular disease**
 age-related, 233
 angiotensin, 233
 biothiols, 127
 ginkgo biloba, 473
 homocysteine, 233
 MAPK phosphorylation, 127
 risk factors, 127
- Caspases**
 peroxiredoxins, 391
 TNF activation, 181, 186
- Catalase**
 cell survival, 386
 diabetes, 222
 DNA synthesis, 367
 lung diseases, 7
 ROS clearance, 10
- Catalysis, thermodynamics, 371–377
- Catecholestrogens, 552
- Cathepsin D, hydroxynonenal, 262
- Cationic liposomes, gene therapy, 13
- Cell death. *See* Apoptosis
- Cells**
 aldehydes, 256
 differentiation, 272, 452
 gene expression, 408
 hydroxynonenal, 257, 265, 272
 metallothioneins, 359
 NO effects, 452
 peroxiredoxins, 385–402
 proliferation, 271
 redox regulation, 408
 stress responses, 303
 survival, 385–396
- Central nervous system (CNS), 487
- Ceramide, nuclear factors, 100
- Cerebral ischemia, ginkgo biloba, 474
- Chemical scavengers, lung diseases, 7
- Chemoattractants. *See* Hydroxynonenal
- Chemoprevention**
 colon cancer, 452, 457
 mechanism-driven, 458
 ROS involvement, 458
- Chemotherapy, cytotoxicity, 563–569
- Children, free radicals, 538, 543
- Chinese medicine, 469
- Chlorogenic acid, colon cancer, 458
- Cholesterol, 529, 586
- Choline deficiency, PBN effects, 482, 488
- Chronic myeloid leukemia (CML), 395
- Chronic obstructive pulmonary disease (COPD), 426, 438
- Cigarette smoke, inhaled oxidant, 427
- Circulation, ginkgo biloba, 475
- Cirrhosis, glutathione, 247
- Cognitive activator, ginkgo biloba, 477
- Colitis, tocopherol, 555–561
- Colon cancer**
 biomarkers, 457
 cells, 455
 diet, 458
 NOS activity, 454
 prevention, 458
 risk factors, 455

- Colon carcinogenesis
 arginine metabolism, 453
 damage scores, 559
 morphology, 557
 RNS involvement, 449–460
Consistent valence force field, 47
- Copper
 binding, 349–361
 complexes, 341
 cytotoxicity, 359
 EPR studies, 351
 hydroxyl radicals, 341
 LDL oxidation, 332
 metallothioneins, 349
 redox signaling, 349
- Copper-zinc superoxide dismutase (CuZnSOD)
 actin reorganization, 30
 gene therapy, 14
 ROS generation, 10, 17
- Creatine kinase, myofibrillar activity, 510, 516
- Crinophagy, B-cells, 306
- Crohn's disease
 antioxidants, 555
 colon cancer, 455
 RNS generation, 455
- Cross-talk, antioxidants, 409–416
- Cyclooxygenase 2 (COX-2), 451
- Cyclophilins, 392
- Cyclosporin A, 396
- Cysteine
 glucocorticoids, 411
 HIV-1 protease, 105–111
 NO effect, 47, 105
 peroxiredoxins, 387
 redox regulation, 411
 sensitivity, 9, 134
 structure, 575
 see also Homocysteine
- Cytochrome P450, 174
- Cytokines
 immune therapy, 250
 IRK inhibition, 45
 lung diseases, 7
 mRNA expression, 491
 oxidative stress, 306
 PBN interaction, 490
 redox activation, 9
 redox signaling, 407
 see also specific cytokine
- Cytoprotection, peroxiredoxins, 385–396
- Cytotoxic T-lymphocytes (CTL), 248
- Death domain**, TNF receptors, 285
- Death-inducing signaling complex (DISC)**, 285
- Degenerative nerve diseases, 474
- Dementia
 AIDS-related, 489
 ginkgo biloba, 476
 PBN effects, 489
- Deoxycholic acid, ROS generation, 456
- Deoxyribonucleic acid (DNA)
 binding, 131, 404
 damage, 450, 459
 episomal, 156
 homocysteine, 365–368
 inflammatory diseases, 459
 lytic amplification, 159
 redox-sensitive, 9, 133
 synthesis, 365–368
 viral suppression, 159
- Diabetes
 adult-onset, 45
 animal models, 525
 children, 212, 460
 clinical data, 214
 endocrine factors, 524
 hyperketonemia, 211–218
 insulin-dependent, 305, 310
 juvenile, 460
 linolenic acid, 523–532
 lipoic acid, 124, 523
 monocytes, 211–218
 oxidative stress, 305, 523
 streptozotocin, 523–532
- Diabetogenesis, drug-induced, 482–488
- Diacylglycerol, 262
- Diamide, phospholipid D, 195
- Dienes, oxidation kinetics, 327, 331
- Diet
 carcinogenesis, 456
 colon cancer, 458–460
 ROS generation, 456
- Dietary supplements
 antioxidants, 79
 database, 4
 epidemiology, 79
- Difluoromethylornithine (DFMO), 458
- Dihydrolipoic acid
 antioxidant, 124
 copper binding, 351
 metallothioneins, 358
- Dimethylpyrrolone oxide (DMPO), 471
- Dimethylsulfoxide (DMSO), 272
- Dimethylthiourea, phospholipase D, 194, 198
- Diphenylpicrylhydral (DPPH)
 absorption spectra, 538
 free radicals, 537–544
 ginkgo biloba, 471
 pH effect, 540
 saliva assay, 537–544
- Diseases
 age-related, 72
 gene therapy, 6, 15
 hydroxynonenal, 259
 redox-mediated, 6–8
 TNF-related, 18
 see also specific disease
- Dithiodipyridine, copper binding, 351
- Dizziness, ginkgo biloba, 476
- Dopaminergic neurons, Parkinson's disease, 137
- Eicosatetraynoic acid, oxidase activity, 172
- Electron flow
 apoptosis, 290
 respiratory chain, 288
 ROS generation, 290
 substrate-specific, 288
 TNF modulation, 288
 XOR catalysis, 375
- Electron paramagnetic resonance (EPR), 351
- Electron spin resonance (ESR), 57, 61
- Electron transport
 apoptosis, 285
 chains, 285–294
 complex activity, 74
 inhibitors, 77
 steroid hormones, 79
 superoxide radicals, 72
 XOR pathways, 372
- Electrophoretic mobility shift assay (EMSA), 183, 319
- Encephalomyelitis, ROI involvement, 137
- Endoplasmic reticulum, intracellular calcium, 504
- Endothelial cells
 actin levels, 30
 adhesion molecules, 83–93
 ginkgo biloba, 475
 hypoxia effect, 30
 metallothioneins, 352
 oxidative stress, 221–229
 phospholipase D, 193–208
 Rac expression, 32
 redox regulation, 193–208
 relaxing factor, 227, 475
 SOD mimicker, 221–229
- Endotoxin shock, 481, 491
- Environmental injury, gene therapy, 5, 14
- Enzymes, redox-modulating, 14
- Epidermal growth factor (EGF), 9
- Epithelial cells, apoptosis, 567
- Epstein-Barr virus (EBV)
 antigen production, 159
 genome suppression, 157
 infection regulation, 155
 plasmids, 157
 redox control, 155–163
 thioredoxin effect, 160
- Erythrocytes
 ginkgo biloba, 475
 peroxiredoxins, 392
- Experimental autoimmune encephalomyelitis (EAE), 137
- Extracellular matrix, liver cells, 268
- Extracellular signal-regulated kinases (ERK)
 calcium ions, 501–506
 cell growth, 124
 hydroxynonenal, 270
- Fas ligand, nuclear factor, 138
- Fats, ROS generation, 456
- Fatty acids, 86
- Fatty streak lesions, 84
- Fenfluramine, neuronal damage, 486
- Ferritin, B-cells, 312

- Fibroblasts**
 actin distribution, 29
 angiotensin signaling, 233
 biothiols, 123–127
 heme catabolism, 267
 MAPK phosphorylation, 123
 PBN effects, 489
- Fibrosarcoma cells, apoptosis, 286**
- Flavin adenine dinucleotide (FAD), 374**
- Flavones, ginkgo biloba, 469**
- Flavonoids**
 antioxidants, 552
 ginkgo biloba, 469
 LDL effects, 589
- Fluorescence-activated cell sorting (FACS), 31**
- Fluorophores, lung imaging, 149**
- Foam cells**
 atherogenesis, 585–591
 formation, 585
 LDL activity, 586
 oxidants, 585
 oxidative stress, 587
- Force production**
 isometric measurement, 511
 myofilaments, 509
 NO effects, 509–520
- Forskolin, IRS-1 inhibition, 118**
- Fos gene**
 homocysteine, 366
 PBN interaction, 490
 redox regulation, 9, 429
- Free radicals**
 aerobic exercise, 537–544
 cysteine targeting, 105–111
 DPPH assay, 537–544
 ginkgo biloba, 469, 476
 HIV-1 protease, 105–111
 Rac expression, 34
 saliva, 537–544
 scavenging activity, 537
 superoxides, 40
- Gag proteins, HIV-1 infection, 105**
- Galvinoxyl radicals, 550**
- Gastric ulcer, PBN effects, 489**
- Gene expression**
 glucocorticoids, 407
 redox regulation, 408
- Gene targeting**
 AAV vector, 13
 novel application, 20
 nuclear factors, 138
 redox-mediated, 12
- Gene therapy, 6–8**
 AAV vector, 13
 adenoviruses, 12
 ARDS patients, 7, 15
 environmental injury, 5, 14
 gutted vectors, 12
 redox-mediated, 5, 13, 18
 retroviruses, 13
 vectors, 12, 20
- Ginkgo biloba**
 action mechanisms, 469
 antioxidant, 470, 472
 bioavailability, 476
 clinical studies, 469–478
 leaf extract, 469
 lipid peroxidation, 472
 oxygen suppression, 473
 pharmacology, 470–476
 scavenging action, 470
 structure, 470
 vascular relaxant, 469
- Glial function, nuclear factor, 130**
- Glucocorticoid receptors**
 amino acid sequences, 405
 cellular model, 415
 coactivator complex, 406
 DNA binding, 412, 412
 GFP analysis, 410
 ligand binding, 409
 protein interactions, 413
 redox regulation, 403–416
 structure and function, 404
 thioredoxin interaction, 416
 transcription regulation, 405
 translocation, 405, 410
- Glucocorticoid response element (GRE), 406**
- Glucocorticoids**
 action mechanisms, 404
 adrenal, 403
 anti-inflammatory agents, 436
 biological implications, 414
 hormone action, 403–408
 molecular mechanisms, 403
 nuclear receptors, 404
 pharmacology, 407, 414
 physiology, 407
 stress responses, 403
- Glucose**
 apoptosis, 289
 B-cells, 311
 contraction, 223
 lipoic acid, 524
 transport, 524
- Glutamine, apoptosis, 288**
- Glutamylcysteine**
 hydroxynonenal, 266
 mechanistic model, 433
 oxidative stress, 432
- Glutathione (GSH)**
 anti-inflammatory agents, 435
 antioxidant genes, 434
 cellular system, 245, 408
 hydroxynonenal, 259
 liver immunity, 245–251
 lung inflammation, 425–439
 mitochondria, 434
 NO inhibition, 48
 phenolic oxidants, 433
 phospholipid D, 194
 proinflammatory mediators, 435
 redox regulation, 425–439
 saliva, 542
 scavenging activity, 542
 synthesis, 430
 TNF signaling, 182
- Glutathione peroxidases, 10**
- Glutathione-S-transferase (GST), 266**
- Glyceryl trinitrate, aortic rings, 223**
- Granulocyte-macrophage colony stimulating factor (GM-CSF), 250**
- Green fluorescent protein (GFP), 410**
- Green tea, NOS inhibition, 459**
- Growth factors, redox signaling, 407**
- Guanosine triphosphate (GTP), 29**
- Guanylic acid, 224, 510**
- Gutted vectors, gene therapy, 12**
- Haloperidol, oxidative stress, 137**
- Heart**
 angiotensin, 233
 calcium uptake, 57
 failure, 233
 muscle, 57, 509
 NO effects, 509
 transcription factor, 234
 XOR reactivity, 376
- Heat shock, NO synthesis, 297–303**
- Heat shock proteins (HSP)**
 glucocorticoids, 404, 410
 nuclear translocation, 410
 oxidative stress, 265
 stress responses, 298
- Hemachromatosis, 306**
- Heme binding protein (HBP), 391**
- Heme oxygenases, 438**
 hydroxynonenal, 267
 redox sensors, 267
- Hepatic stellate cells, 268**
- Hepatocarcinogenesis, 482, 488**
- Hepatitis, immune therapy, 249**
- Herpesviruses. See Epstein-Barr virus**
- High-density lipoproteins (HDL), 590**
- Homocysteine**
 angiotensin signaling, 233
 atherosclerosis, 365, 368
 DNA synthesis, 365–368
 fibroblasts, 123–127
 fos expression, 236
 MAPK phosphorylation, 123
 peroxide mechanism, 365
 SRF activation, 236
 VSMC proliferation, 365
- Hormones**
 cross-talk, 409–416
 glucocorticoids, 403–408
 redox regulation, 409–416
 stress responses, 409
- Human immunodeficiency virus (HIV)**
 glutathione, 245
 peroxiredoxins, 386
 protease inhibitors, 108
 redox imbalance, 428
- HIV-1**
 bacterial expression, 107
 cysteine targeting, 105
 free radicals, 105–111
 peroxiredoxins, 395
 protease structure, 106

- Human T-cell lymphotropic virus (HTLV), 156
- Huntington's disease, peroxiredoxins, 394
- Hydrogen peroxide
cytotoxicity, 308
DNA synthesis, 365–368
glucocorticoids, 412
homocysteine, 365
hydroxyl radicals, 341
intracellular calcium, 501
MAPK activation, 501–506
neuronal damage, 134
phospholipase D, 194
redox signaling, 356
SAPK activation, 113–120
second messenger, 131
VSMC proliferation, 365
- Hydroxyl alkenals (HAK)
action mechanism, 260
bioactive molecules, 263
chemotactic stimuli, 263
lipid peroxides, 255
liver diseases, 267
proinflammatory, 263
- Hydroxyhexenal, chemotaxis, 263
- Hydroxyl radicals
ginkgo biloba, 471
lipid oxidation, 341
membrane permeability, 342
time course, 341
- Hydroxynonenal
action mechanism, 255
adduct formation, 257–261
atherosclerosis, 258, 261
biological signal, 261–272
cellular response, 265–267
chemical reactivity, 257
G-proteins, 261
gene expression, 271
liver diseases, 258, 273
metabolism, 257–261
molecular basis, 255
nervous system, 257
oxidative stress, 265
pathophysiology, 261–272
profibrogenic molecule, 267
signal transduction, 261
ultraviolet response, 267
- Hydroxyoctenal, chemotaxis, 263
- Hyperhomocysteinemia, 123, 126
- Hyperketonemia, diabetes, 211–218
- Hypertension, cell growth, 167
- Hypoxanthine, 61, 371
- Hypoxia, lung damage, 15, 30
- I**
- Idiopathic pulmonary fibrosis (IPF)
glutathione, 426
inflammation, 438
redox imbalance, 428
- Immunodeficiency, *See* Human immunodeficiency virus
- Infection, lytic and latent, 155–163
- Inflammation
cellular, 455
glucocorticoids, 415
mediators, 429
NO protection, 455
thiols, 438
see also Lung inflammation
- Inflammatory bowel disease (IBD)
antioxidants, 555
colon cancer, 455
RNS generation, 455
- Inhaled oxidants, 427
- Inorganic antioxidants, 542
- Inositol, 56, 262
- Insulin
lipoic acid, 527
metabolic effects, 524
see also Diabetes
- Insulin receptor kinase (IRK)
modeling, 47, 49
mutant proteins, 46
NO inhibition, 45–52
phosphorylation, 45
redox sensitivity, 52
- Insulin receptor substance (IRS), 115, 118
- Insulinoma, oxidative stress, 310
- Insulinitis, autoimmune, 305
- Intercellular adhesion molecule 1 (ICAM-1), 84, 89
- Interferon- γ
IRK inhibition, 45
NOS regulation, 297
PBN interaction, 490
TNF secretion, 300
- Interleukin-2
EBV replication, 156
LAK activity, 389
liver cancer, 248
NOS regulation, 297
- Interleukin converting enzyme (ICE), 452
- Interleukins, PBN interaction, 490
- International Bibliographic Information on Dietary Supplements (IBIDS), 4
- Iron
B-cells, 312
complexes, 513
lysosomes, 306
NO affinity, 513
oxidative stress, 306
sulfur centers, 371, 374
XOR catalysis, 371
- Ischemia
calcium imaging, 145
intravital microscopy, 147
lung cells, 145–152
NO formation, 518
ROS inhibitors, 150
- Ischemia-reperfusion
activator protein, 317–323
Bcl expression, 321
gene therapy, 6, 16
ginkgo biloba, 473
hydroxynonenal, 259
injury, 6, 16, 145, 473, 486
PBN effects, 485
redox regulation, 317–323
ROS generation, 145, 317
transcription factors, 317
- Jaundice, PBN effects, 488
- Jun genes, redox regulation, 428
- Jun kinases, antioxidant regulation, 181–190
- Jun N-terminal kinase (JNK)
action mechanisms, 113–120
apoptosis, 181–190
calcium, 501–506
hydrogen peroxide, 113
hydroxynonenal, 267, 269
peroxiredoxins, 391, 395
redox imbalance, 428
TNF activation, 186
- Jurkat cells, endothelial adhesion, 86, 92
- Juvenile diabetes, 460, 489
- K**
- Kaempferol, ginkgo biloba, 469, 476
- Kaposi's sarcoma, peroxiredoxins, 395
- Ketosis, diabetes, 211–218
- Kidney, arginase, 453
- Kupffer cells, liver, 250
- L**
- Langerhans islets, oxidative stress, 310
- Latent infections, 155–163
- Lentiviruses, gene therapy, 13
- Leucine, angiotensin, 170
- Leukemic cells, hydroxynonenal, 272
- Leukemogenesis, peroxiredoxins, 395
- Leukocytes, ginkgo biloba, 475
- Levodopa, peroxynitrite, 243
- Licorice, LDL antioxidant, 589
- Life span, PBN effects, 487
- Ligand binding domain (LBD), 404
- Linolenic acid
animal models, 525
blood glucose, 527
densitometry, 529
diabetes, 523–532
insulin response, 527
metabolic effects, 523
- Lipid bilayers
oxidative changes, 339–345
planar membranes, 341
stability and permeability, 339
- Lipid hydroperoxidases, 84
- Lipid hydroperoxides, 93, 328
- Lipid peroxidation
antioxidants, 547–553
cellular processes, 382
ginkgo biloba, 472
hydroxynonenal, 271
PQQ action, 547–553
redox signaling, 352
tocopherol, 555
- Lipid peroxides, inhibitors, 185
- Lipoic acid
animal models, 525
antioxidants, 361
blood glucose, 527

- Lipoic acid** (*continued*)
 diabetes, 523–532
 fibroblasts, 123–127
 glucose transport, 524
 insulin response, 527
 MAPK phosphorylation, 123
 metabolic effects, 523
 peroxynitrites, 239–244
- Liposomes**
 gene therapy, 13
 oxidative changes, 340
 small unilamellar, 328
- Lipoxygenases**
 activity and expression, 83
 adhesion molecules, 83–93
 endothelial cells, 83
 enzyme activity, 87, 89
 mRNA expression, 87
 VSMC hypertrophy, 168, 176
- Liver**
 animal studies, 247
 arginase, 453
 CTL activity, 248
 damage, 17
 gene expression, 267
 glutathione, 245
 immunity, 245–251
 lipid peroxidation, 256
 lipoic acid, 530
- Liver diseases**
 cancer, 248
 hydroxynonenal, 258, 273
 types, 258
- Low-density lipoproteins (LDL)**
 acetyl receptor, 588
 acyl chains, 327, 330
 aggregation, 586
 antioxidants, 325, 589
 arteriosclerosis, 474
 atherosclerosis, 585
 diene accumulation, 329
 ginkgo biloba, 471, 474
 hydroxynonenal, 258, 264
 lipoxygenase, 83
 oxidation, 325–337, 586, 590
 oxygenases, 588
 PBN effects, 489
 peroxiredoxins, 391
 peroxynitrite, 239
 redox state, 7
 retention, 586
 structure, 326
 tocopherol, 327, 333
- Luminol**, copper oxidation, 352, 355
- Lung cells**
 anti-inflammatory agents, 455
 calcium imaging, 145–152
 GCS regulation, 432
 glutathione, 431–435
 hyperoxia damage, 15
 ischemia, 145–152
 microvascular, 145
 oxidative stress, 432
 ozone response, 265
- Lung diseases**, redox-mediated, 7
- Lung inflammation**
 epithelial cells, 425
 glutathione, 425–439
 inhaled oxidants, 427
 mediators, 429
 oxidants, 426
 redox regulation, 425
 transcription factors, 428
- Lymphocyte function-associated**
 antigen 1 (LFA-1), 93
- Lymphocytes**, liver-associated, 247
- Lymphokine-activated killer cells**
 (LAK), 248, 389
- Lysophosphatidic acid (LPA)**, 206
- Lysosomes**
 apoptosis, 305
 B-cells, 305–312
 membrane stability, 308
 necrosis, 305
 oxidative stress, 305
- Lytic infections**, 155–163
- Macrophage stress proteins (MSP)**, 390
- Macrophages**
 atherogenesis, 585–591
 azacytidine, 297–303
 foam cells, 585
 heat shock, 297
 metabolic labeling, 298
 oxidants, 585–591
 stress response, 297–303
 TNF secretion, 297
- Malonyldialdehyde (MDA)**, 255
- Manganese superoxide dismutase**
 (MnSOD)
 gene therapy, 14, 138
 ROS generation, 10, 17
- Mercaptopropionylglycine (MPG)**, 194, 197
- Messenger RNA (mRNA)**, 87, 459
- Metal-induced oxidation**, lipoproteins, 336
- Metallothioneins**
 bifunctional, 349–361
 cellular protection, 359
 copper binding, 349
 DHLA generation, 358
 EPR spectra, 357
 native and oxidized, 355
 redox signaling, 349–361
 structure, 350
- Metastasis**, RNS involvement, 454
- Methoxytryptamine**, peroxynitrite inhibition, 239–244
- Methyl linoleate**, PQQ inhibition, 551
- Milk**, oxidase activity, 376
- Mitochondria**
 androgens, 71–79
 apoptosis, 285–294
 calcium, 505
 electron flux, 285
 electron transport, 78
 inhibitors, 99
 muscle myotubes, 97–103
 nuclear factors, 97
- oxidative stress, 71–79
 peroxiredoxins, 392
 prostate cancer, 71–79
 respiratory chain, 100
 ROS generation, 16
 testosterone effect, 78
 TNF signaling, 97–103
- Mitogen-activated protein kinases**
 (MAPK)
 biothiols, 123–127
 calcium, 501–506
 fibroblasts, 123
 hydrogen peroxide, 501
 lipoic acid, 123
 phosphorylation, 123
 ROS formation, 17
- Mitogenesis**, free radicals, 40
- Molybdopterin**, XOR catalysis, 371, 374
- Monocytes**
 apoptosis, 211–218
 diabetes, 211
 hyperketonemia, 211
- Multiple sclerosis**, ROI involvement, 134, 137
- Muscle**
 antioxidants, 524
 cells, 45
 chronic disease, 97
 IRK phosphorylation, 45
 linolenic acid, 528
 lipoic acid, 530
 mRNA levels, 529
 myotubes, 97–103
 TNF signaling, 97
 vascular disorders, 6
see also Vascular smooth muscle cells
- Myc gene**, 271, 366
- Myocardium**, oxidative damage, 510
- Myofilaments**, cardiac, 509–520
- Myosin light chains**, 519
- Myotubes**, TNF signaling, 97–103
- N-acetyl-L-cysteine (NAC)**
 liver cancer, 248
 phospholipid D, 194
 thiol inflammation, 438
 TNF signaling, 182
- N-ethylmaleimide**, HIV protease, 109
- National Institutes of Health (NIH)**, 3
- Natural killer cells (NK)**, 389
- Necrosis**
 B-cells, 305–312
 ginkgo biloba, 474
 lysosomes, 305
 oxidative stress, 305
- Nervous system**
 hydroxynonenal, 257
 nuclear factor, 129–139
 oxidative stress, 134
 ROI activation, 129
- Neurodegeneration**, drug-induced, 486
- Neuronopathy**, ginkgo biloba, 474
- Neuroprotective agents**, 136
- Neurotoxic peptides**, Alzheimer's disease, 137

- Neutrophils, 264, 489
- Niacinamide, juvenile diabetes, 460
- Nicotinamide adenine dinucleotide (NAD)
ADPR conversion, 65
conversion reactions, 59
XOR catalysis, 371, 375
- Nicotinamide adenine dinucleotide, reduced form (NADH)
apoptosis, 293
electron donor, 375
measuring, 169
oxidase activity, 167
VSMC hypertrophy, 167
- Nicotinamide adenine dinucleotide phosphate, reduced form (NADPH)
flow cytometry, 287
LDL oxidation, 588
hydroxynonenal, 264
measuring, 169
oxidase activity, 167
phagocytes, 34
Rac expression, 34
redox capacity, 289
ROS generation, 16
TNF effect, 289
VSMC hypertrophy, 167
- Nicotinic acid
colon carcinogenesis, 459
DNA damage, 459
juvenile diabetes, 460
- Nitrates, colon carcinogenesis, 456
- Nitration, selective inhibitors, 239–244
- Nitric oxide (NO)
arginine metabolism, 453
autoregulatory loops, 138
azacytidine, 297–303
calcium sensitivity, 509–520
cell differentiation, 452
colon carcinogenesis, 449
costimulation, 139
cysteine targeting, 105–111
diabetes, 222
ESR analysis, 511
force production, 509
heat shock, 297–303
HIV-1 protease, 105–111
intracellular effects, 509
IRK phosphorylation, 45–52
macrophages, 297
microbicidal activity, 111
myofibrillar function, 509
nuclear factors, 101
PBN interactions, 491
physiology, 509, 517
polyamines, 454
production, 138
responsive targets, 509
ROS clearance, 12
saliva, 544
second messenger, 138
spin-trapping reagents, 513
urea cycle, 454
vascular injury, 18
- Nitrites, dietary inhibition, 459
- Nitrogen oxygen synthetase (NOS)
Alzheimer's disease, 137
colon carcinogenesis, 449, 454
COX-2 activation, 451
enzyme activity, 450
gene expression, 12
nervous system, 137
ROS clearance, 12
TNF activation, 102
vascular injury, 18
- Nitrones
pharmacology, 481–492
spin-trapping agents, 481
structures, 483
types, 483
- Nitrosation, HIV-1 protease, 105–111
- Nitrosothiols, 109
- Nitrosylation, IRK modeling, 49
- Non-insulin dependent diabetes mellitus (NIDDM), 45
- Nonprotein antioxidants, 540
- Nonsteroidal anti-inflammatory drugs (NSAID), 458
- Nordihydroguaiaretic acid (NDGA), 170
- Nuclear factor κ B
activation, 131
adhesion molecules, 83–93
antioxidant regulation, 181–190
atherosclerosis, 93
binding activity, 320
calcium probes, 101
cholinergic stimulation, 136
crystal structure, 133
endothelial cells, 83–93
heat shock, 302
lipoxygenase expression, 83–93
lung inflammation, 429
mitochondrial signaling, 97
muscle myotubes, 97–103
nervous system, 97–103
NO activation, 451
PBN interaction, 491
peroxiredoxins, 391, 395
redox regulation, 317–323
ROI activation, 97–103
signal transduction, 100
TNF activation, 130
- Nuclear localization signal (NLS), 8, 405
- Nutrition. *See* Diet
- Oatmeal, colon cancer, 459
- Obesity, IRK activity, 45
- Office of Dietary Supplements (NIH), 3
- Oncogenesis, free radicals, 40
- Organs
ischemia-reperfusion, 6
multiple failure, 7
pathophysiology, 16
redox damage, 20
- Ornithine decarboxylase, 453
- Osteoblastic specific factor (OSF), 391
- Oxidants
aortic cells, 34
atherogenesis, 585
caspase blockage, 186
cell-derived, 426
environmental, 427
foam cells, 585–591
inflammation, 426
inhaled, 427
types, 325
- Oxidase activation, angiotensin, 167–176
- Oxidation
damage, 325, 489
lipid bilayers, 339–345
metal-induced, 336, 489
PBN effects, 489
prevention, 325–337
see also Redox regulation
- Oxidative stress
aging, 72, 474
androgens, 71–79
apoptosis, 305
B-cells, 305–312
biological membranes, 345
copper-mediated, 488
diabetes, 124, 523
endothelial cells, 221
foam cells, 587
glutathione, 432
homocysteine, 366
hydroxynonenal, 265
inflammation, 435
insulinoma, 310
intracellular calcium, 501
lipid bilayers, 349–345
lysosomal stability, 305–312
metallothioneins, 350
mitochondria, 71–79
necrosis, 305–312
nervous system, 134
plasma markers, 529
prostate cancer, 71–79
SAPK activation, 113–120
SOD mimicker, 221–229
systemic markers, 524
tissue markers, 529
vascular disorders, 7
viral infections, 162
- Oxygen suppression, ginkgo biloba, 473
- Oxysterols, atherogenesis, 586
- Ozone
inhaled oxidant, 427
lung cells, 265
- Pancreatic cells, thioredoxin, 312
- Paraoxonase, 590
- Parkinson's disease
ginkgo biloba, 474
peroxiredoxins, 394
ROI involvement, 134
- Parvoviruses, gene therapy, 13
- Pellagra, Crohn's disease, 459
- Peptide hormones, redox signaling, 407

- Peroxidation, phospholipids, 340
- Peroxides
- decomposition, 328
 - reactivity, 326
- Peroxiredoxins
- aggregation, 389, 394
 - amino acid sequence, 388
 - apoptosis, 395
 - biological implications, 393
 - brain tissue, 393
 - cell survival, 385–396
 - cysteine, 387
 - cytoprotection, 385–396
 - dimerization, 394
 - features, 388
 - gene expression, 393
 - multifactorial, 385
 - organ distribution, 393
 - reaction cycle, 389
 - tissue expression, 393–396
 - tumor suppression, 385–396
 - types, 386
- Peroxyl radicals
- ginkgo biloba, 471
 - lipid oxidation, 340
 - PQQ interaction, 550
 - trap assay, 328, 331
- Peroxynitrite
- antioxidant, 239–244
 - lipoic acid, 239
 - mitochondria, 450
 - oxidation, 242
 - selective inhibitors, 239
 - tyrosine nitration, 239
- Phagocytes, Rac expression, 34
- Phenolic antioxidants, 433, 552
- Phenylbutylnitron (PBN)
- anti-aging effects, 487
 - antidote models, 488
 - brain tissue, 483
 - chemical properties, 482
 - cytokine interaction, 490
 - mechanistic studies, 490–492
 - metabolites, 482
 - mRNA expression, 491
 - patents, 492
 - pharmacology, 481–492
 - physical properties, 482
 - scavenging mechanism, 482
 - vasodilator, 485
- Phorbol myristate acetate (PMA), 9, 92
- Phosphatidylcholine, 340
- Phosphatidylinositol, SAPK activation, 113–120
- Phospholipases
- hydroxynonenal, 261, 264
 - nuclear factors, 102
 - redox regulation, 193–208
 - ROS stimulation, 194
 - VSMC hypertrophy, 173
- Phospholipids
- endothelial cells, 193–208
 - hydroxynonenal, 262
 - peroxidation, 340
 - ROS clearance, 12
- Phosphoproteins, SAPK activation, 116
- Phosphorylation
- IRK activity, 45–52
 - NO inhibition, 45
 - SAPK activation, 113
- Physical exercise, free radicals, 537–544
- Plasmid-DNA vectors, gene therapy, 13
- Platelet-activating factor (PAF), 469, 475
- Platelet-derived growth factor (PDGF), 116, 270
- Polyamines, NO production, 454
- Polyneuropathy, diabetic peripheral, 523
- Polyphenol antioxidants, 552
- Polyunsaturated fatty acids (PUFA), hydroxynonenal, 269
- LDL oxidation, 328
 - peroxidation, 255
- Potassium, liposome release, 341, 345
- Pravastatin, peroxiredoxins, 396
- Proanthocyanidins, chemotherapy, 563–569
- Procollagen, hydroxynonenal, 268
- Proinflammatory genes, 93, 434
- Proliferation-associated genes, 389
- Prostacyclin, ginkgo biloba, 475
- Prostaglandins, diabetes, 532
- Prostate cancer
- aging, 72
 - androgens, 72
 - mitochondria, 71–79
 - oxidative stress, 71
 - ROS levels, 75
- Protein-DNA complexes, gene targeting, 13
- Protein kinase C (PKC), 98, 262
- Pulmonary fibrosis, redox regulation, 7
- Pyrogallol, contraction, 223
- Pyrrolidine dithiocarbamate (PDTC)
- nuclear factor, 131
 - PBN interaction, 490
 - TNF signaling, 182
- Pyrroloquinolinequinol (PQQ)
- absorption spectra, 549
 - antioxidant, 547–553
 - galvinoxyl radicals, 550
 - lipid peroxidation, 547
 - peroxyl radicals, 550
 - reduction and stability, 548
 - tocopherol, 552
- Quercetin, ginkgo biloba, 469, 476
- Rac proteins
- acetyl cysteine, 35
 - actin reorganization, 29
 - endothelial cells, 32
 - free radicals, 34
 - gene therapy, 20
 - redox activation, 9
- Radiation-induced fibrosis, 14
- Radical scavengers, glucocorticoids, 416
- Raji cells, EBV replication, 156
- Raloxifen, 406
- Reactive nitrogen species (RNS)
- cellular stressors, 382
 - colon carcinogenesis, 449
 - DNA damage, 450
 - enzyme activity, 451
 - generation, 455
 - inflammatory cells, 455
 - metastasis, 454
 - signaling pathways, 460
 - transcription factors, 451
 - tumorigenesis, 454
- Reactive oxygen intermediates (ROI)
- generation mechanisms, 134
 - intracellular calcium, 501
 - lipid peroxidation, 255
 - neuronal damage, 134
 - nervous system, 129–139
 - nuclear factor, 129
 - TNF production, 136
 - types, 134
- Reactive oxygen species (ROS)
- apoptosis, 285–294
 - cancer, 72, 455
 - carcinogenesis, 449–460
 - cells, 18, 386, 408
 - clearance pathways, 10–12
 - colon cancer, 455
 - diabetes, 221
 - DPPH assay, 537–544
 - electron flux, 285–294
 - environmental injury, 13, 19
 - flow cytometry, 287
 - gene therapy, 13
 - generation, 19, 455
 - homocysteine, 123
 - inflammatory cells, 455
 - ischemia, 148
 - lung inflammation, 427
 - mitochondria, 98, 285
 - muscle cells, 98, 100
 - organ transplantation, 6
 - peroxiredoxins, 386
 - responses, 19
 - saliva, 537–544
 - signal transduction, 101
 - stressors, 382
 - thiol-redox schematic, 207
 - TNF signaling, 98, 182
 - toxic compounds, 21
 - types, 7, 194
 - vascular disorders, 7, 194
- Red blood cells. *See* Erythrocytes
- Red wine, LDL inhibitor, 589
- Redox factor, global role, 9
- Redox regulation
- activator proteins, 317–323
 - ARDS patients, 7
 - cell models, 408, 415
 - cross-talk, 408
 - diseases, 6–8
 - DNA binding, 412
 - EBV control, 155–163
 - endothelial cells, 193–208
 - fos genes, 428
 - gene expression, 408
 - gene therapy, 6, 13, 18

- glucocorticoid receptors, 403
 glutathione, 425–439
 growth factors, 9
 hormone action, 409–416
 inflammation, 425–439
 ischemia-reperfusion, 317–323
 Jun genes, 428
 lung inflammation, 425–439
 nuclear factors, 317–323
 phospholipase D, 193–208
 pulmonary fibrosis, 7
 transcription factors, 317
Redox Regulation of Cell Signaling and Its Clinical Application (Packer and Yodoi), book review, 381
 Redox signaling
 biochemical mechanisms, 382
 cellular reactions, 381
 clinical applications, 381
 copper binding, 349–361
 cytokines, 407
 DHLA inhibition, 359
 early and late, 181–190
 growth factors, 9, 407
 hydrogen peroxide, 356
 ischemia-reperfusion, 317
 lipid peroxidation, 392
 metallothioneins, 349–361
 modulation, 13–18
 physiologic systems, 382
 potential checkpoints, 132
 thioredoxin, 381
 transcription factors, 317
 vascular disorders, 208
 Regulatory factors, gene therapy, 20
 Relaxation responses, aortic rings, 223
 Relaxing factor, endothelial cells, 517
 Reperfusion. *See* Ischemia-reperfusion
 Repressor proteins, 8, 18
 Restenosis, 7, 167
 Retinoblastoma gene, muscle proliferation, 21
 Retroviral gene transfer, 84
 Retroviruses, gene therapy, 13
 Rigor contracture
 crossbridges, 515
 cysteine kinase, 518
 NO effects, 512, 516
 Rosemary, NOS inhibition, 459
 Rotenone
 apoptosis, 290
 electron transport, 77
 mitochondria, 99
 TNF inhibition, 99
 Ryanodine receptor, calcium release, 56
S-nitroso-N-acetylpenicillamine (SNAP)
 HIV inhibition, 106, 108
 insulin receptor, 47
 Saliva, free radical scavenging activity
 age and sex, 542
 DPPH assay, 537
 fractionation, 541
 free radicals, 537–544
 Sarcoplasmic reticulum
 ADPR activity, 55–67
 ESR analysis, 57, 61
 heavy vesicles, 56
 superoxides, 55–67
 Scavenger proteins, cell survival, 386
 Second messengers, nitric oxide, 138
 Secretory granules, B-cells, 306, 312
 Selenium, colon cancer, 458
 Sepsis, redox-regulated, 7
 Serum response factor (SRF), 126
 Sick cell disease, peroxiredoxins, 392
 Signal transduction
 G-proteins, 261–263
 hydroxynonenal, 261
 nuclear factor, 130
 Signal transduction pathways (STP)
 actin reorganization, 29
 activation, 7
 modulation, 18–21
 redox-mediated, 8, 18
 types, 7
 Skeletal muscle
 antioxidants, 524
 IRK phosphorylation, 45
 linolenic acid, 528
 myotubes, 97–103
 TNF signaling, 97
 Skinned fiber technique, cardiac myofilaments, 510
 Small nuclear ring finger protein (SNURF), 414
 Smooth muscle cells. *See* Vascular smooth muscle cells
 Sodium nitroprusside, HIV inhibition, 108, 110
 Sphingomyelinase, nuclear factors, 100
 Spin-trapping agents, 481
 Stem cells, transplantation, 564
 Streptozotocin, diabetes, 488
 Stress. *See* Oxidative stress
 Stress-activated protein kinase (SAPK)
 action mechanism, 113–120
 apoptosis, 502
 hydrogen peroxide, 113
 hydroxynonenal, 267
 intracellular calcium, 501
 Stress responses
 adrenal glucocorticoids, 403
 antioxidants, 409–416
 hormones, 409–416
 macrophages, 297–303
 Striatum, PBN effects, 487
 Stroke
 gene therapy, 6
 PBN effects, 481
 peroxiredoxins, 394
 Sulfhydryls, 358, 414
 Superoxide dismutases (SOD)
 endothelial dysfunction, 221–229
 extracellular form, 10
 diabetes, 222
 lung diseases, 7
 mimic compound, 221
 oxidative stress, 221
 Rac expression, 35
 ROS clearance, 10
 types, 10
 Superoxides
 actin reorganization, 29
 anion radicals, 55–67
 calcium release, 55
 diabetes, 222
 endothelial cells, 221
 free radicals, 40
 ginkgo biloba, 491
 JNK activation, 40
 mitogenesis, 40
 neuronal damage, 134
 novel mechanisms, 55
 radical quenchers, 182
 sarcoplasmic reticulum, 55
 Supplements. *See* Dietary supplements
 Synthetic antioxidants, 239–244
T-cells, endothelial adhesion, 83–93
 Tamoxifen, 406
 Testosterone, prostate cancer, 72
 Thalidomide, teratogenicity, 482, 488
 Thapsigargin, 113, 504
 Thiobarbituric acid (TBA)
 diabetes, 526
 oxidative stress, 529
 tocopherol effect, 560
 Thiol-specific antioxidants (TSA)
 amino acid sequences, 576
 structure and function, 571
 types, 571–582
 Thiols
 cell assays, 195, 246
 hydrogen peroxide, 202
 inflammation, 438
 intracellular, 193–208
 liver and muscle, 526, 530
 metallothioneins, 351
 nuclear factors, 131
 peroxidation, 356
 phospholipid D, 194
 ROS effects, 199
 types, 439
 see also Biothiols
 Thioredoxin
 cell system, 408
 DNA binding, 9
 EBV replication, 155–163
 infection regulation, 155
 Thymidine, DNA synthesis, 366
 Tissue
 hydroxynonenal, 257–261
 peroxiredoxins, 393–396
 Tocopherol
 colitis, 555–561
 colon cancer, 458, 557
 diabetes, 527
 LDL levels, 327, 333
 neuroprotective agent, 136
 oxidative stress, 529
 PQQ interaction, 552
 prostate cancer, 77
 saliva, 542
 structure, 556

- Tocopherol (*continued*)
 TBA effect, 560
 water-soluble, 555
- Transcription factors
 ischemia-reperfusion, 317
 oxidant-sensitive, 426
 PBN interaction, 491
 redox regulation, 317–323
 RNS activation, 451
 types, 9
- Transforming growth factor- β , 268, 436
- Transmission electron microscopy (TEM), 307
- Transplantation, peroxiredoxins, 396
- Transporter proteins, NO inhibition, 45
- Traumatic shock, PBN effects, 482
- Trinitrobenzene sulfonic acid, 555
- Troponins, NO effects, 519
- Tumor necrosis factor (TNF)
 antimycin A, 99
 antioxidants, 181–190
 antiproliferative effects, 188
 apoptosis, 181, 285
 azacytidine, 297–303
 cytotoxicity, 183
 electron flux, 285–294
 heat shock, 297–303
 mitochondria, 285
 regulation, 285–294
 signaling, 181–190
- TNF- α
 azacytidine, 297–303
 environmental injury, 17
 heat shock, 297–303
 IRK inhibition, 45
 lipxygenase activation, 89
 lung diseases, 7
 macrophages, 297–303
 mitochondria, 97
- muscle myotubes, 97
 PBN interaction, 490
 phospholipase activator, 102
 ROS generation, 17
 signaling, 97–103
- Tumorigenesis, arginine metabolism, 453
- Turmeric, NOS inhibition, 459
- Tyrosine
 nitration, 239–244
 oxidation, 239
 phosphorylation, 198, 204
 thiols, 198
- Tyrosine kinase
 autophosphorylation, 46
 inhibitors, 262
 intracellular calcium, 503
- Ulcerative colitis
 antioxidants, 555
 colon cancer, 455
 RNS generation, 455
- United States Department of Agriculture (USDA), 3
- Urea cycle, NO production, 454
- Uric acid, scavenging activity, 542
- Vascular cell adhesion molecule 1 (VCAM-1), 83–93
- Vascular disorders
 gene therapy, 18, 21
 homocysteine, 366
 oxidative stress, 7
 redox signaling, 208
- Vascular endothelial growth factor (VEGF), 438
- Vascular smooth muscle cells (VSMC)
 angiotensin, 167–176
 arachidonic acid, 167
- atherosclerosis, 365
 gene therapy, 21
 homocysteine, 365–368
 hydrogen peroxide, 365
 hypertrophy, 167–176
 oxidase activity, 167
 peroxide mechanism, 365
 proliferation, 365–368
- Vasoactive substances, 532
- Vasoconstrictors
 cell growth, 167
 ginkgo biloba, 475
- Vectors, gene therapy, 12, 15, 20
- Viral infections, oxidative stress, 162
- Vitamin C. *See* Ascorbic acid
- Vitamin E. *See* Tocopherol
- Vitamin and Mineral Laboratory (USDA), 3
- Vitreoretinopathy, ginkgo biloba, 474
- Wortmaninn, SAPK activation, 116
- Xanthine dehydrogenase (XDH)
 catalysis, 371
 interconversion, 373
 specificity, 374
- Xanthine oxidase
 catalysis, 371
 specificity, 374
 systems, 10, 16
- Xanthine oxidoreductase (XOR)
 electron transfer, 372
 equilibrium model, 372
 pH experiments, 373
 pulse radiolysis, 373
 redox centers, 375
 thermodynamics, 371–377
- Zinc, B-cells, 306